Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.
Taral Patel

Dr. Taral Patel MD

Oncologist, MID-OHIO ONCOLOGY & HEMOTOLOGY INC

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Member of the Healthcare Council

Council Member Biography

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the advisory board for several drug companies including Amgen, Novartis, Lilly, Genetech, and Aventis. (This is me - Update Profile)


Employment History

1999 - Unspecified
Oncologist, MID-OHIO ONCOLOGY & HEMOTOLOGY INC

GLG NewsSM Analyses by Taral Patel(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Avastin In Breast cancer

February 19, 2008

In Second Trial, Avastin Is Found Effective in Treating Breast Cancer | www.nytimes.com

New data with low and high dose of Avastin with Taxoter

improve Overall survival in prostate cancer

February 19, 2008

Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival | www.pipelinereview.com

esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received PROVENGE, as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022). Data is very impressive. This may lead FDA approval in prostate cancer in next 3-6 months.

Avastin in breast cancer

December 7, 2007

F.D.A. Criticizes Avastin Use for Breast Cancer | www.nytimes.com

“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never used Avastin to treat breast cancer, but he knows other doctors do, despite the lack of FDA’s blessing. “Physicians always want to do something for the patient,” he said. But he believes the panel’s vote “will make them think twice” before they try Avastin for breast cancer. “This drug is a good drug,” Buzdar added. “It does work in a number of other cancers where it not only prolongs control of the disease but it keeps more patients alive. In breast cancer, it has not panned out.”

CMS

August 29, 2007

New Medicare Regulations Adopted To Reduce Certain Hospital Infections And Medical Errors | www.medicalnewstoday.com

CMS is doing right thing. This will aviod pt fall and bedsore during hospitalzation

ERBITUX

August 9, 2007

Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program | www.pipelinereview.com

The comprehensive clinical program will supplement the significant body of clinical data existing for ERBITUX in colorectal and head and neck cancers by exploring the use of ERBITUX in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate

View All GLG News SM Analyses by Taral Patel

Leading institutions connect with Taral Patel through GLG

GLG Live Meetings with Taral Patel(?)

Taral Patel has not participated in any GLG Live Meetings.

View all GLG Live Meetings in Healthcare